CLOTRIMADERM VAGINAL 6 CREAM

国: カナダ

言語: 英語

ソース: Health Canada

即購入

製品の特徴 製品の特徴 (SPC)
29-04-2022

有効成分:

CLOTRIMAZOLE

から入手可能:

TARO PHARMACEUTICALS INC

ATCコード:

G01AF02

INN(国際名):

CLOTRIMAZOLE

投薬量:

1%

医薬品形態:

CREAM

構図:

CLOTRIMAZOLE 1%

投与経路:

VAGINAL

パッケージ内のユニット:

50GM

処方タイプ:

OTC

治療領域:

AZOLES

製品概要:

Active ingredient group (AIG) number: 0110231001; AHFS:

認証ステータス:

APPROVED

承認日:

2020-02-21

製品の特徴

                                _PAGE 1 OF 22_
_ _
_CLOTRIMADERM VAGINAL 6 _
_CLOTRIMADERM VAGINAL 3 _
_CLOTRIMADERM EXTERNAL CREAM _
PRODUCT
MO
N
OG
RA
PH
CLOTRIMADERM VAGINAL 6
(Clotrimazo le
Vaginal Cream USP 1%)
CLOTRIMADERM VAGINAL 3
(Clotrimazo le
Vaginal Cream USP 2%)
CLOTRIMADERM EXTERNAL C
RE
AM
(Clotrimazole
Vaginal Cream USP 1%)
ANTIFUNGAL
AG
E
NT
Taro Pharmaceuticals
Inc. Date of Revision:
130 East Drive
April 29, 2022
Brampton,
Ontario
L6T 1C1
CONTROL #263252
_PAGE 2 OF 22_
_ _
_CLOTRIMADERM VAGINAL 6 _
_CLOTRIMADERM VAGINAL 3 _
_CLOTRIMADERM EXTERNAL CREAM _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
3
CONTRAINDICATIONS
.............................................................................................................
3
WARNINGS AND
PRECAUTIONS.............................................................................................
3
ADVERSE REACTIONS
.............................................................................................................
4
DRUG INTERACTIONS
..............................................................................................................
5
DOSAGE AND
ADMINISTRATION...........................................................................................
6
OVERDOSAGE
............................................................................................................................
6
ACTION AND CLINICAL PHARMACOLOGY
......................................................................
6
STORAGE AND
STABILITY.......................................................................................................
8
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................................. 8
PART II: SCIENTIFIC INFORMATION
....
                                
                                完全なドキュメントを読む
                                
                            

この製品に関連するアラートを検索

ドキュメントの履歴を表示する